The research was carried out to establish a new reverse phase-HPLC stability indicating method for quantifying Bimatoprost & Timolol in ophthalmic solution. The experiment of Bimatoprost & Timolol in ophthalmic soluti...
AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (lOP) on current therapy. METHODS: Pre- and pos...
Supported by the National Outstanding Youth Science Fund Project(No.81202726)
AIM: To draw a Meta-analysis over the comparison of the intraocular pressure (lOP)-lowering efficacy and safety between the commonly used fixed-combinations of prostaglandin analogs and 0.5% timolol with prostaglan...
funded by Allergan,Inc.(Irvine,CA,USA)through Nexus Medicals S.A.,the exclusive distributor of Allergan products in Greece.Qualitis Ltd.,a contract research organization in Zografou,Greece,was responsible for data management in the study
AIM:To evaluate the efficacy and tolerability of the fixed combination of bimatoprost 0.03%and timolol 0.5%(BTFC)in patients in Greece with primary open angle glaucoma(POAG)or ocular hypertension(OHT)whose prev...
Objectives: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of bimatoprost 0.03%/timolol 0.50%, timolol 0.50% or bimatoprost 0.01% eye drops. Methods: This is a pr...
Background Lowering intraocular pressure (lOP) is currently the only therapeutic approach in primary open-angle glaucoma.and the fixed-combination medications are needed to achieve sufficiently low target lOP.A mult...
Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed...